These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11885733)

  • 1. Meningococcal vaccination for adolescents? An economic evaluation in Victoria.
    Skull SA; Butler JR
    J Paediatr Child Health; 2001 Oct; 37(5):S28-33. PubMed ID: 11885733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation.
    Skull SA; Butler JR; Robinson P; Carnie J
    Int J Epidemiol; 2001 Jun; 30(3):571-8; discussion 578-9. PubMed ID: 11416085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccinating first-year college students living in dormitories for Meningococcal disease: an economic analysis.
    Scott RD; Meltzer MI; Erickson LJ; De Wals P; Rosenstein NE
    Am J Prev Med; 2002 Aug; 23(2):98-105. PubMed ID: 12121797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
    Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
    Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City.
    Simon MS; Weiss D; Geevarughese A; Kratz MM; Cutler B; Gulick RM; Zucker JR; Varma JK; Schackman BR
    J Acquir Immune Defic Syndr; 2016 Feb; 71(2):146-54. PubMed ID: 26334735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
    Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
    Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health impact and cost-effectiveness of introducing the vaccine (Bexsero) against MenB disease into the Brazilian immunization programme.
    Moura Silveira M; McBride AJA; Trotter CL
    Vaccine; 2019 Oct; 37(45):6783-6786. PubMed ID: 31570182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
    Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada.
    Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B
    Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults.
    Leeds IL; Namasivayam V; Bamogo A; Sankhla P; Thayer WM
    Am J Prev Med; 2019 Feb; 56(2):196-204. PubMed ID: 30573332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.
    Whittles LK; Didelot X; White PJ
    Lancet Infect Dis; 2022 Jul; 22(7):1030-1041. PubMed ID: 35427491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges and opportunities for meningococcal vaccination in the developing world.
    Shaker R; Fayad D; Dbaibo G
    Hum Vaccin Immunother; 2018 May; 14(5):1084-1097. PubMed ID: 29393729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales.
    Trotter CL; Edmunds WJ
    BMJ; 2002 Apr; 324(7341):809. PubMed ID: 11934772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program.
    Bos JM; Rümke HC; Welte R; Postma MJ; Jager JC
    Vaccine; 2001 Oct; 20(1-2):202-7. PubMed ID: 11567765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis.
    Gasparini R; Landa P; Amicizia D; Icardi G; Ricciardi W; de Waure C; Tanfani E; Bonanni P; Lucioni C; Testi A; Panatto D
    Hum Vaccin Immunother; 2016 Aug; 12(8):2148-2161. PubMed ID: 27163398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
    Welte R; van den Dobbelsteen G; Bos JM; de Melker H; van Alphen L; Spanjaard L; Rümke HC; Postma MJ
    Vaccine; 2004 Dec; 23(4):470-9. PubMed ID: 15530695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel.
    Ginsberg GM; Block C; Stein-Zamir C
    Int J Public Health; 2016 Jul; 61(6):683-692. PubMed ID: 27105884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.